Alto Neuroscience (ANRO) Income from Continuing Operations (2023 - 2026)

Alto Neuroscience has disclosed Income from Continuing Operations across 4 years of filings, most recently posting 26122000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 26122000.0, down 80.81% year-over-year; the trailing twelve-month figure through Mar 2026 was 73905000.0 (down 18.42% YoY), and the FY2025 annual result was 62230000.0, down 1.79% from the prior year.
• Income from Continuing Operations came in at 26122000.0 for Q1 2026 at Alto Neuroscience, down from 16069000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 7295000.0 in Q1 2023 to a low of 26122000.0 in Q1 2026.
• The 4-year median for Income from Continuing Operations is 14447000.0 (2025), against an average of 14332000.0.
• Across the five-year window, Income from Continuing Operations sank 82.47% in 2024 and climbed 15.93% in 2025, its largest moves.
• Alto Neuroscience's Income from Continuing Operations stood at 11383000.0 in 2023, then sank by 33.49% to 15195000.0 in 2024, then declined by 5.75% to 16069000.0 in 2025, then slumped by 62.56% to 26122000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 26122000.0 (Q1 2026), 16069000.0 (Q4 2025), and 14069000.0 (Q3 2025), per Business Quant data.